Today (December 1), Benovas Pharmaceutical Joint Stock Company – a subsidiary of Cuu Long Pharmaceutical Joint Stock Company (DCL) and Canada’s Pharmascience pharmaceutical company officially became a strategic partner.
The signing ceremony is taking place in Ho Chi Minh City, Vietnam.
Accordingly, becoming a strategic partner of Pharmascience help Benovas diversify its product portfolio, especially with First – To-Market products, which is a great advantage for Benovas in accelerating the process of marketing. access, expand markets and offering better service for patients.
At the same time, it accesses the world pharmaceutical market through the supply chain of Pharmascience – one of the major pharmaceutical manufacturing companies in Canada as well as the global pharmaceutical industry.
Mr. Nguyen Van Sang Chairman of the Board of Directors of FIT Group on behalf of Benovas signs the strategic cooperation agreement with Mr. Nguyen Vu Khanh – Head of Representative Office of Pharmascience in APAC region
Addressing about Benovas becoming a strategic partner of Pharmascience, Mr. Nguyen Vu Khanh – Head of Representative Office of Pharmascience Asia – Pacific (APAC) said: “We are looking forward to the cooperation with the pharmaceutical presentation team. Benovas’ superior membership, distribution system and market access enable us to supply high quality medicinal products to the Vietnamese market”.
At the signing ceremony, the Benovas leadership representative said that becoming a strategic partner offering Vietnam global quality pharmaceutical products originating from Canada, helping Vietnam’s pharmaceutical industry to diversify, supplies and provides Vietnamese doctors as also medical staff with more options in disease prevention and treatment.
Mr. Nguyen Van Sang and Mr. Nguyen Vu Khanh answered questions from press agencies
“For us, our core value is to take care of consumers’ health in a dedicated and humane way, along with various up-to-date and modern innovations, preserving our commitment inwards activities. Therefore, through this signing ceremony, our potential product portfolio only focuses on cardiovascular, oncology, central nervous system and diabetes product groups. In the future, after Benovas builds a pharmaceutical factory that meets FDA (Food and Drug Administration) standards issued by the US Food and Drug Administration, Pharmascience will transfer it to Benovas to produce and distribute the products of Pharmascience, not only at the distribution of products as the initiation process of cooperation,” said a Benovas representative.
Also according to the representative of Benovas, in the coming time, Pharmasciense will be responsible for developing and supplying high quality medicinal products to the Vietnamese market through Benovas’ sales and distribution system; Benovas is responsible for the sales and marketing activities to achieve the goals set by both companies and meet the diverse treatment needs of the Vietnamese medical staff.
Benovas is a leading pharmaceutical company in the field of trade and distribution in Vietnam. Currently Benovas is a pharmaceutical enterprise with a well-organized sales team covering both ETC & OTC channels; Distribution network stretches with 12 branches nationwide and 4 distribution centers.
Pharmascience is one of the major pharmaceutical manufacturing companies in Canada founded in 1983 with more than 1,500 employees and is distributing products to nearly 50 countries worldwide.
Pharmascience’s global presence and steady growth have enabled patients and healthcare providers worldwide to access the same high-quality pharmaceutical products as The Canadians.
Pharmascience’s R&D team is highly-expertised and professional who are key factors in the development of complex injectable and oral generics.
Pharmascience manufactures and distributes high quality pharmaceutical products with a factory system in Candiac that has been certified by FDA (USA) since 2017.
During its formation and development, Pharmascience has invested more than 500 million dollars in product research and development and currently standing among the leading pharmaceutical manufacturing companies in Canada, providing more than 300 product lines of products with more than 20 dosage forms.
Particularly in Canada, Pharmascience pharmaceutical products are prescribed for more than 45 million prescriptions each year.
